GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LianBio (OTCPK:LIANY) » Definitions » FCF Yield %

LianBio (LianBio) FCF Yield % : -229.41 (As of Jun. 04, 2024)


View and export this data going back to 2021. Start your Free Trial

What is LianBio FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, LianBio's Trailing 12-Month Free Cash Flow is $-83.99 Mil, and Market Cap is $36.61 Mil. Therefore, LianBio's FCF Yield % for today is -229.41%.

The historical rank and industry rank for LianBio's FCF Yield % or its related term are showing as below:

LIANY' s FCF Yield % Range Over the Past 10 Years
Min: -323.85   Med: 0   Max: 0
Current: -229.41


LIANY's FCF Yield % is ranked worse than
93.69% of 1553 companies
in the Biotechnology industry
Industry Median: -14.22 vs LIANY: -229.41

LianBio's FCF Margin % for the quarter that ended in Sep. 2023 was 0.00%.


LianBio FCF Yield % Historical Data

The historical data trend for LianBio's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LianBio FCF Yield % Chart

LianBio Annual Data
Trend Dec19 Dec20 Dec21 Dec22
FCF Yield %
- - -24.95 -57.55

LianBio Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -31.20 -70.52 -33.61 -31.71 -40.14

Competitive Comparison of LianBio's FCF Yield %

For the Biotechnology subindustry, LianBio's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LianBio's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LianBio's FCF Yield % distribution charts can be found below:

* The bar in red indicates where LianBio's FCF Yield % falls into.



LianBio FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

LianBio's FCF Yield % for the fiscal year that ended in Dec. 2022 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-101.03 / 175.55216
=-57.55%

LianBio's annualized FCF Yield % for the quarter that ended in Sep. 2023 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-16.024 * 4 / 159.68181
=-40.14%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LianBio FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


LianBio FCF Yield % Related Terms

Thank you for viewing the detailed overview of LianBio's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


LianBio (LianBio) Business Description

Traded in Other Exchanges
N/A
Address
103 Carnegie Center Drive, Suite 215, Princeton, NJ, USA, 08540
LianBio is a science-driven biopharmaceutical company dedicated to developing and commercializing medicines for patients with unmet medical needs, with an initial focus on in-licensing assets for Greater China and other Asian markets. It is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, inflammatory disease, and respiratory indications.
Executives
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Wei Wei Chen director C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 309, PRINCETON NJ 08540
Debra Yu officer: See Remarks C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
C2 Life Sciences Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Lev Lb Holdings Gp, Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Venture Advisors, Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Susan Michele Silbermann director C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Brianne Jahn officer: Chief Business Officer C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Yizhe Wang director, officer: Chief Executive Officer 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Jiang Qian officer: China General Manager C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Lev Lb Holdings, Lp 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Xontogeny Venture Fund, Lp 10 percent owner C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Yi Larson officer: Chief Financial Officer C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Neil Kumar director C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304